WHO Drug Information Vol. 25, No. 2, 2011

WHO Drug Information Vol. 25, No. 2, 2011 Proposed INN: List 105dabrafenibN-{3-[5-(2-aminopirimidin-4-il)-2-terc-butil-1,3-tiazol-4-il]-2-fluorofenil}-2,6-difluorobencenosulfonamidoantineoplásicoC 23 H 20 F 3 N 5 O 2 S 2 1195765-45-7NH 2FNNFF SHCHN3SNO O H 3 C CH 3daclatasvirumdaclatasvirdaclatasvirdaclatasvirdimethyl N,N'-([1,1'-biphenyl]-4,4'-diylbis{1H-imidazole-5,2-diyl-[(2S)-pyrrolidine-2,1-diyl][(1S)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamateantiviralN,N'-([1,1'-biphényl]-4,4'-diylbis{1H-imidazole-5,2-diyl-[(2S)-pyrrolidine-2,1-diyl][(1S)-3-méthyl-1-oxobutane-1,2-diyl]})dicarbamate de diméthyleantiviralN,N'-([1,1'-bifenil]-4,4'-diilbis{1H-imidazol-5,2-diil-[(2S)-pirrolidina-2,1-diil][(1S)-3-metil-1-oxobutano-1,2-diil]})dicarbamato de dimetiloantiviralC 40 H 50 N 8 O 6 1099119-64-5CH 3H 3 COCH 3HONHHNONNHHNNNHHNOOOHCH 3CH 3CH 3dalanterceptum #dalanterceptfusion protein for immune applications (FPIA) comprising Homosapiens ACVRL1 (activin A receptor type II-like 1, activin receptorlikekinase 1, ALK1, ALK-1, serine/threonine-protein kinase receptorR3, SKR3, transforming growth factor-beta superfamily receptor typeI, TGF-B superfamily receptor type I, TSR-I, HHT2, ORW2)fragment, fused with Homo sapiens immunoglobulin G1 Fc fragment;ACVR2L1, 22-120 precursor fragment (1-99) -threonyl-triglycyl (100-103) -gamma1 chain H-CH2-CH3 fragment (104-328) [Homosapiens IGHG1*03 hinge 8-15 (104-111), CH2 L1.3>A (115), G1>A(118), A115>V (211) (112-221), CH3 S85.3>P (284) (222-328)];(107-107':110-110')-bisdisulfide dimerantineoplastic165